Sight Sciences, Inc. (NASDAQ:SGHT) EVP Buys $19,250.00 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Manohar K. Raheja purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The stock was acquired at an average price of $3.85 per share, for a total transaction of $19,250.00. Following the purchase, the executive vice president now owns 111,000 shares of the company’s stock, valued at approximately $427,350. This represents a 4.72 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Sight Sciences Trading Up 3.1 %

NASDAQ SGHT opened at $3.99 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a one year low of $2.71 and a one year high of $8.45. The company has a 50-day simple moving average of $4.82 and a 200-day simple moving average of $6.01. The firm has a market capitalization of $202.53 million, a PE ratio of -3.91 and a beta of 2.58.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. On average, equities analysts forecast that Sight Sciences, Inc. will post -1.01 earnings per share for the current year.

Institutional Trading of Sight Sciences

Several hedge funds have recently bought and sold shares of SGHT. Steele Capital Management Inc. bought a new position in Sight Sciences in the 2nd quarter worth about $67,000. SG Americas Securities LLC bought a new position in Sight Sciences in the 3rd quarter worth approximately $75,000. The Manufacturers Life Insurance Company acquired a new stake in Sight Sciences in the 2nd quarter valued at approximately $95,000. GSA Capital Partners LLP bought a new stake in Sight Sciences during the 3rd quarter valued at $136,000. Finally, American Century Companies Inc. boosted its position in Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after acquiring an additional 8,527 shares during the period. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Morgan Stanley reduced their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, November 11th. Piper Sandler reissued a “neutral” rating and set a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Lake Street Capital downgraded Sight Sciences from a “buy” rating to a “hold” rating and decreased their price target for the stock from $10.00 to $5.00 in a research note on Monday, November 4th. Finally, UBS Group initiated coverage on Sight Sciences in a research note on Friday. They set a “buy” rating and a $5.50 price objective on the stock. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.50.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.